The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients

Schizophr Res. 2004 May 1;68(1):11-9. doi: 10.1016/j.schres.2003.07.001.

Abstract

Background: Chronic schizophrenia patients have been sampled for factor analytic studies to identify the factor structure of the Positive and Negative Syndrome Scale (PANSS). Many of these studies have identified a cognitive factor, which may provide useful information about patients for whom formal neuropsychological testing is unavailable. However, the relationship between the clinically rated cognitive factor and performance-based cognitive test scores has not been thoroughly examined, particularly in patients who are early in the course of illness.

Objectives: The validity of the PANSS cognitive factor was examined in a sample of antipsychotic naïve, first-episode psychosis patients and the PANSS items that best predicted cognitive functioning were identified.

Method: PANSS scores and performance on a battery of cognitive tests from the baseline assessment of a clinical trial of 167 neuroleptic naïve patients with schizophrenia-like illnesses were analyzed.

Results: Factor analysis revealed a five-factor model that was consistent with previously described factor models from samples of chronically treated patients. There were modest correlations (less than r=0.44) between the derived cognitive factor and six of the neuropsychological test variables (Wisconsin Card Sorting Test total errors and number of categories correctly sorted, WMS-R immediate and delayed recall scores, Category Fluency total score, and WAIS-R digit symbol). Five PANSS items (P6, N5, N6, G2, and G10) were identified that predicted global cognitive functioning; however, 66% of the variance in cognitive functioning remained unexplained.

Conclusions: A PANSS cognitive factor can be identified in first-episode, neuroleptic naïve patients. However, clinical ratings of cognitive deficits lack sensitivity and specificity and thus should not be relied upon fully.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Chronic Disease
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / etiology*
  • Double-Blind Method
  • Factor Analysis, Statistical
  • Female
  • Haloperidol / therapeutic use*
  • Humans
  • Male
  • Neuropsychological Tests*
  • Reproducibility of Results
  • Schizophrenia / complications*
  • Schizophrenia / drug therapy*
  • Severity of Illness Index
  • Surveys and Questionnaires*

Substances

  • Antipsychotic Agents
  • Haloperidol